ProQR Therapeutics (NASDAQ:PRQR) PT Raised to $2.00 at Citigroup

ProQR Therapeutics (NASDAQ:PRQR - Free Report) had its price target upped by Citigroup from $1.80 to $2.00 in a research report sent to investors on Thursday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company's stock.

PRQR has been the subject of a number of other research reports. StockNews.com lowered ProQR Therapeutics from a buy rating to a hold rating in a research report on Tuesday, March 19th. Chardan Capital upped their price target on ProQR Therapeutics from $2.00 to $2.50 and gave the company a buy rating in a research report on Thursday, March 14th. Finally, HC Wainwright reaffirmed a buy rating and set a $5.00 price target on shares of ProQR Therapeutics in a research report on Thursday, March 14th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of Moderate Buy and an average price target of $3.60.

ProQR Therapeutics Trading Down 2.1 %

Shares of NASDAQ PRQR traded down $0.04 during midday trading on Thursday, reaching $1.86. The company had a trading volume of 182,612 shares, compared to its average volume of 286,021. ProQR Therapeutics has a one year low of $1.11 and a one year high of $3.29. The company has a quick ratio of 3.54, a current ratio of 3.54 and a debt-to-equity ratio of 0.10. The firm's fifty day moving average price is $2.14 and its 200-day moving average price is $1.87. The stock has a market cap of $151.33 million, a PE ratio of -4.77 and a beta of 0.21.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last released its earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.08). ProQR Therapeutics had a negative return on equity of 56.71% and a negative net margin of 431.65%. The company had revenue of $3.54 million during the quarter, compared to analyst estimates of $27.88 million. On average, equities research analysts anticipate that ProQR Therapeutics will post -0.37 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Belvedere Trading LLC purchased a new position in shares of ProQR Therapeutics during the 4th quarter worth approximately $42,000. Tower Research Capital LLC TRC grew its holdings in shares of ProQR Therapeutics by 164.8% during the 1st quarter. Tower Research Capital LLC TRC now owns 14,132 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 8,796 shares during the period. BNP Paribas Financial Markets grew its holdings in shares of ProQR Therapeutics by 137.3% during the 4th quarter. BNP Paribas Financial Markets now owns 15,901 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 9,200 shares during the period. Mariner LLC purchased a new position in shares of ProQR Therapeutics during the 4th quarter worth approximately $68,000. Finally, Two Sigma Securities LLC purchased a new position in shares of ProQR Therapeutics during the 1st quarter worth approximately $41,000. Hedge funds and other institutional investors own 32.65% of the company's stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).